[MeMed in The Times of Israel] MeMed partners with Italy’s DiaSorin to commercialize bacteria vs virus test

MeMed Diagnostics, a Haifa-based firm that develops diagnostic solutions to monitor the body’s immune state, said it will partner with Italian diagnostic firm DiaSorin to commercialize a test that is able to distinguish between bacterial and viral infections.

Read more here.

The post [MeMed in The Times of Israel] MeMed partners with Italy’s DiaSorin to commercialize bacteria vs virus test appeared first on OurCrowd Blog.

OurCrowd Blog

[Nexa3D in Today’s Medical Developments] Nexa3D, Henkel jointly commercialize high impact, durable material

“We developed and tested a multitude of approved workflows designed to unleash the full potential of xMED412’s outstanding physical properties and biocompatibility,” says Ken Kisner, Henkel’s head of innovation for 3D printing.  “Nexa3D and Henkel have provided a digital manufacturing solution for a growing number of medical devices, athletic wearables, and personalized audio products.

Read more here.

The post [Nexa3D in Today’s Medical Developments] Nexa3D, Henkel jointly commercialize high impact, durable material appeared first on OurCrowd Blog.

OurCrowd Blog

[BlueNalu in Aju Business Daily] Pulmuone signs deal to commercialize BlueNalu’s cell-based seafood in S. Korea

Through collaboration with BlueNalu, a U.S. cellular aquaculture company, Pulmuone, a food company based in Seoul,  jumped into the commercialization of healthy cell-based seafood products without genetic modification and free of environmental contaminants in South Korea where the demand for seafood is high.

Read more here.

The post [BlueNalu in Aju Business Daily] Pulmuone signs deal to commercialize BlueNalu’s cell-based seafood in S. Korea appeared first on OurCrowd.

OurCrowd